The Board of Directors of Sanofi India Limited, at its meeting held on October 26th 2021 have approved the unaudited Standalone financial results of the company for the period ended September 30, 2021
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
FDI increased 98% year on year in 2020 and pharma exports grew by 18% in the last financial year
Filing marks first protein-based vaccine submitted to MHRA for authorization
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
A total of 12 generic medicines have been included in the list
Support from DFC will help produce one billion vaccine doses by the end of 2022
The list of kids with co-morbidities eligible for vaccination would be announced by the government
Subscribe To Our Newsletter & Stay Updated
